ALX ONCOLOGY HOLDINGS INC — Investor Relations & Filings

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that enhance the immune system's ability to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 blocking agent designed to maximize clinical activity while minimizing inherent toxicities. Evorpacept is engineered to block the CD47 checkpoint pathway, a signal used by cancer cells to evade the immune system. The company is advancing a broad clinical development program for evorpacept in combination with other anti-cancer agents for the treatment of various hematologic malignancies and solid tumors. The strategic goal is to establish evorpacept as a cornerstone therapy that can be integrated with current and future standards of care.